US2017326081A1PendingUtilityA1
Genotype- or phenotype-based drug formulation
Est. expiryJun 1, 2032(~5.9 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 43/00A61P 15/08A61K 31/138C07C 213/08G06F 19/12A61K 45/06G16B 5/00
39
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to a combination of two or more pharmaceutically active substances, of which at least one is a metabolic product (“metabolite”) of the other (“parent substance”), wherein in particular the dosages thereof are selected such that genotypically or phenotypically related variability in the conversion of the parent substance to the metabolite in particular individuals is compensated for.
Claims
exact text as granted — not AI-modified1 . A fixed-dose combination pharmaceutical formulation comprising tamoxifen and endoxifen.
2 . The formulation according to claim 1 , comprising 15-25 mg of tamoxifen and 0.25-5.0 mg of endoxifen.
3 . The formulation according to claim 2 adapted for CYP2D6 IM patients, comprising 15-25 mg of tamoxifen and 0.25-2.00 mg of endoxifen.
4 . The formulation according to claim 2 adapted for CYP2D6 PM patients, comprising 15-25 mg of tamoxifen and 1.0-5.0 mg of endoxifen.Join the waitlist — get patent alerts
Track US2017326081A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.